205 related articles for article (PubMed ID: 37884686)
1. Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin.
Olafsson S; Rodriguez E; Lawson ARJ; Abascal F; Huber AR; Suembuel M; Jones PH; Gerdes S; Martincorena I; Weidinger S; Campbell PJ; Anderson CA
Nat Genet; 2023 Nov; 55(11):1892-1900. PubMed ID: 37884686
[TBL] [Abstract][Full Text] [Related]
2. Systemic lupus erythematosus: association with psoralen--ultraviolet-A treatment of psoriasis.
Eyanson S; Greist MC; Brandt KD; Skinner B
Arch Dermatol; 1979 Jan; 115(1):54-6. PubMed ID: 760658
[TBL] [Abstract][Full Text] [Related]
3. The Science and (Lost) Art of Psoralen Plus UVA Phototherapy.
Richard EG
Dermatol Clin; 2020 Jan; 38(1):11-23. PubMed ID: 31753184
[TBL] [Abstract][Full Text] [Related]
4. The role of PUVA in the treatment of psoriasis. Photobiology issues related to skin cancer incidence.
Gasparro FP
Am J Clin Dermatol; 2000; 1(6):337-48. PubMed ID: 11702610
[TBL] [Abstract][Full Text] [Related]
5. The ultraviolet fingerprint dominates the mutational spectrum of the p53 and Ha-ras genes in psoralen + ultraviolet A keratoses from psoriasis patients.
Wolf P; Kreimer-Erlacher H; Seidl H; Bäck B; Soyer HP; Kerl H
J Invest Dermatol; 2004 Jan; 122(1):190-200. PubMed ID: 14962108
[TBL] [Abstract][Full Text] [Related]
6. High frequency of ultraviolet mutations at the INK4a-ARF locus in squamous cell carcinomas from psoralen-plus-ultraviolet-A-treated psoriasis patients.
Kreimer-Erlacher H; Seidl H; Bäck B; Cerroni L; Kerl H; Wolf P
J Invest Dermatol; 2003 Apr; 120(4):676-82. PubMed ID: 12648234
[TBL] [Abstract][Full Text] [Related]
7. Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?
Lindelöf B
Drug Saf; 1999 Apr; 20(4):289-97. PubMed ID: 10230579
[TBL] [Abstract][Full Text] [Related]
8. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy.
Vallat VP; Gilleaudeau P; Battat L; Wolfe J; Nabeya R; Heftler N; Hodak E; Gottlieb AB; Krueger JG
J Exp Med; 1994 Jul; 180(1):283-96. PubMed ID: 7516410
[TBL] [Abstract][Full Text] [Related]
9. Psoralen photochemotherapy, clinical efficacy, and photomutagenicity: the role of molecular epidemiology in minimizing risks.
Gasparro FP; Liao B; Foley PJ; Wang XM; McNiff JM
Environ Mol Mutagen; 1998; 31(2):105-12. PubMed ID: 9544188
[TBL] [Abstract][Full Text] [Related]
10. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study.
Stern RS; Liebman EJ; Väkevä L
J Natl Cancer Inst; 1998 Sep; 90(17):1278-84. PubMed ID: 9731734
[TBL] [Abstract][Full Text] [Related]
11. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis.
Doppalapudi S; Jain A; Chopra DK; Khan W
Eur J Pharm Sci; 2017 Jan; 96():515-529. PubMed ID: 27777066
[TBL] [Abstract][Full Text] [Related]
12. The active compounds derived from Psoralea corylifolia for photochemotherapy against psoriasis-like lesions: The relationship between structure and percutaneous absorption.
Alalaiwe A; Hung CF; Leu YL; Tahara K; Chen HH; Hu KY; Fang JY
Eur J Pharm Sci; 2018 Nov; 124():114-126. PubMed ID: 30153523
[TBL] [Abstract][Full Text] [Related]
13. Resolution of psoriatic lesions in erythematous skin induced by PUVA treatment.
Vukas A; Batistić B; Zambal Z
Acta Med Iugosl; 1979; 33(2):147-53. PubMed ID: 506793
[No Abstract] [Full Text] [Related]
14. [Photochemotherapy of psoriasis using a Soviet-made furocoumarin preparation psorberan].
Kapkaev RA; Liuban BL; Akovbian VA
Vestn Dermatol Venerol; 1983 Dec; (12):48-50. PubMed ID: 6369824
[No Abstract] [Full Text] [Related]
15. Photochemotherapy (PUVA) and psoriasis: comparison of 8-MOP and 8-MOP/5-MOP.
Langner A; Wolska H; Kowalski J; Duralska H; Murawska E
Int J Dermatol; 1976 Nov; 15(9):688-9. PubMed ID: 977210
[TBL] [Abstract][Full Text] [Related]
16. Interaction of methotrexate and betamethasone with experimental phototoxic inflammation to PUVA (Psoralen and UVA) in mice.
Ljunggren B; Möller H
Arch Dermatol Res; 1979 Mar; 264(2):257-60. PubMed ID: 464643
[TBL] [Abstract][Full Text] [Related]
17. [Photochemotherapy with the external use of psoberan in psoriasis patients].
Krivatkin SL
Vestn Dermatol Venerol; 1987; (7):60-2. PubMed ID: 3673248
[No Abstract] [Full Text] [Related]
18. Psoralen-UVA-treated psoriatic lesions. Ultrastructural changes.
Hashimoto K; Kohda H; Kumakiri M; Blender SL; Willis I
Arch Dermatol; 1978 May; 114(5):711-22. PubMed ID: 646392
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and histological evaluation of oral psoralen plus UV-A exposure (PUVA) for treating psoriasis vulgaris (author's transl)].
Jimbow K; Nishio C; Uesugi T; Katoh M; Kato M; Makita A; Chiba M; Horikoshi T
Nihon Hifuka Gakkai Zasshi; 1978; 88(1):23-36. PubMed ID: 306462
[No Abstract] [Full Text] [Related]
20. Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with fitzpatrick skin type IV.
Khurshid K; Haroon TS; Hussain I; Pal SS; Jahangir M; Zaman T
Int J Dermatol; 2000 Nov; 39(11):865-7. PubMed ID: 11123453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
